Article: A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
AuthorsLau, GKK
Lie, AKW
Kwong, YL
Lee, CK
Hou, J
Lau, YL
Lim, WL
Liang, R1
Issue Date2000
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
CitationBlood, 2000, v. 96 n. 2, p. 452-458 [How to Cite?]
AbstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.
ISSN0006-4971
2011 Impact Factor: 9.898
2011 SCImago Journal Rankings: 1.698
ISI Accession Number IDWOS:000088234800011
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLau, GKK
dc.contributor.authorLie, AKW
dc.contributor.authorKwong, YL
dc.contributor.authorLee, CK
dc.contributor.authorHou, J
dc.contributor.authorLau, YL
dc.contributor.authorLim, WL
dc.contributor.authorLiang, R
dc.date.accessioned2010-09-06T07:27:32Z
dc.date.available2010-09-06T07:27:32Z
dc.date.issued2000
dc.description.abstractTo compare the clinical and serological outcomes of patients receiving donors' marrow positive or negative for hepatitis B surface antigen (HBsAg), we studied 18 patients of allogeneic hematopoietic cell transplantation receiving HBsAg-positive marrow (group 1) and 18 receiving HBsAg-negative marrow (group 2). The recipients of the 2 groups were matched for hepatitis B virus (HBV) serology, sex, age, underlying hematological diseases, conditioning regimen, and prophylaxis against graft-versus-host diseases. Eight (44.4%) recipients in group 1 and 2 (11.1%) in group 2 suffered from HBV- related hepatitis posttransplant (P = .03). Furthermore, HBV-related hepatic failure was seen in 6 group 1 patients, but in none of the group 2 patients (P = .007). Five of the 9 (55.5%) HBsAg-negative recipients in group 1 became positive after receiving HBsAg-positive marrow. Serum HBV DNA was positive in all 5 donors of these patients, but in none of the donors of recipients who remained HBsAg negative (P = .008). Group 1 patients developing HBV-related hepatitis posttransplant were more likely to have a donor carrying a precore A 1896 and/or core promoter T 1762/A 1764 HBV variant (62.5% versus 0%, P = .007). This study has demonstrated that a high incidence of HBV-related hepatitis was associated with the use of HBsAg- positive marrow for transplant, and a high viral load in the donor appeared to predispose recipients to the development of HBV-related hepatitis posttransplant. Further clinical trials will be necessary to determine the optimal management approach to this problem, including the use of the antiviral agents in the donors and the recipients. (C) 2000 by The American Society of Hematology.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationBlood, 2000, v. 96 n. 2, p. 452-458 [How to Cite?]
dc.identifier.epage458
dc.identifier.hkuros55820
dc.identifier.isiWOS:000088234800011
dc.identifier.issn0006-4971
2011 Impact Factor: 9.898
2011 SCImago Journal Rankings: 1.698
dc.identifier.issue2
dc.identifier.openurl
dc.identifier.pmid10887105
dc.identifier.scopuseid_2-s2.0-0034661838
dc.identifier.spage452
dc.identifier.urihttp://hdl.handle.net/10722/77032
dc.identifier.volume96
dc.languageeng
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
dc.publisher.placeUnited States
dc.relation.ispartofBlood
dc.relation.referencesReferences in Scopus
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBone Marrow Cells - virology
dc.subject.meshCase-Control Studies
dc.subject.meshFemale
dc.subject.meshHematopoietic Stem Cell Transplantation
dc.subject.meshHepatitis B - etiology - mortality
dc.subject.meshHepatitis B Antibodies - blood
dc.subject.meshHepatitis B Surface Antigens - analysis
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshTissue Donors
dc.titleA case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong